Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Soumerai JD, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri AR, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan K, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A Jr.
Soumerai JD, et al. Among authors: harkins s.
Blood. 2022 Oct 20;140(16):1822-1826. doi: 10.1182/blood.2022015443.
Blood. 2022.
PMID: 35802834
Free PMC article.
No abstract available.